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To determine if HFNC use was associated with changes in incidence of BPD and ROP. 
 
Methods 
This retrospective study examined premature infants (<30 weeks GA or <1500g) in a tertiary neonatal unit from 2010-
2016. Patients were compared before and after introduction of HFNC. Further analysis of high-risk infants (<28 weeks 
GA or <750g or ventilated) compared those who received HFNC to those who did not across the whole period. Primary 
outcomes were incidence of BPD and ROP requiring surgery.  
 
Results 
Incidence of BPD rose following the introduction of HFNC (82/232 (35.3%) after vs 33/251 (13.1%) before, p<0.001).  
On multivariate analysis, the chance of developing BPD after HFNC introduction remained higher (OR 4.353, 95% CI 
2.546-7.443). More infants received surgery for ROP following HFNC introduction (0/214 vs 11/205 (5.4%), p=<0.001). 
In the second analysis, the rate of BPD was higher in those who received HFNC (90/132 (68.1%) vs 33/153 (21.6%), 
p<0.001).  Receiving HFNC demonstrated higher chance of BPD in multivariate analysis (OR 7.802, 95% CI 4.223-14.423).  
Rate of ROP surgery was higher in those who received HFNC (0/153 vs 13/134 (9.7%), p<0.001). 
 
Conclusions 






High-flow nasal cannulae (HFNC) as respiratory support have been increasingly adopted in neonatal units due to 
benefits including reduced nasal trauma, being less invasive, allowing teat-feeding and involving parents in infant-
cares, when compared to nasal continuous positive airway pressure (CPAP)1. 
 
In our Neonatal Unit, HFNC are used as a weaning tool from CPAP in premature very low birth weight (VLBW) infants. 
Randomised controlled trials (RCT) comparing HFNC with CPAP in this context have reported contradictory results. 
Soonsowad et al showed that weaning from CPAP via HFNC, versus continuing CPAP and weaning directly to air, lead 
to no difference in time to wean from respiratory support, rates of BPD or rates of severe ROP (≥stage 3 ROP)2. Two 
other RCTs published on this topic yield conflicting results with one showing infants receiving HFNC had a longer 
duration of respiratory support3, and the other reporting decreased length of total oxygen therapy associated with 
HFNC use4. Observational studies also show inconsistent results regarding respiratory outcomes and ROP.  While 
increased rates of bronchopulmonary dysplasia (BPD) and/or longer duration of respiratory support are associated 
with HFNC, there are conflicting associations between HFNC use and rates of ROP5-8. 
This study explores the relationship between introduction of HFNC as a means of weaning VLBW infants from 
respiratory support and rates of BPD, ROP and length of stay in a  tertiary neonatal unit.  
 
 
Methods   
 
This retrospective review in a single tertiary NICU compared outcomes before and after the introduction of HFNC as a 
means of weaning infants off CPAP.  All patients admitted to the unit were eligible for inclusion if their birthweight 
was less than 1500g or their gestational age (GA) less than 30 weeks, they did not have significant congenital 
malformation and they did not die in within 12 hours of admission. Data were extracted from an existing database for 
the years 2010-2016, inclusive. Patients were split into two epochs; before (2010-2012) and after the introduction of 
HFNC (2014-2016), with 2013 being disregarded as an implementation phase. For additional analyses, we defined a 
priori a subset of patients considered to be ‘eligible’ for HFNC (defined as babies with GA<28 weeks, birthweight <750g, 
ventilated or received surfactant and did not die before discharge). Within this subset of patients, those infants who 
were supported with HFNC were compared to those who did not receive HFNC support.  
The primary outcomes were BPD (defined as oxygen dependence at 36 weeks CGA) and severe ROP requiring surgical 
treatment (laser photocoagulation, anti-VEGF treatments not included in analysis as only introduced 2011). Secondary 
outcomes included length of stay, any stage of ROP (see below for definitions) and pneumothorax (if seen on chest X-
Ray). 
 
HFNC were used as a tool to wean infants from CPAP when greater than 2 weeks of age and stable on CPAP according 
to specific criteria (PEEP ≤5cm, Fi02≤30%, pH ≥7.25 and no significant apneas). The starting flow was 5-6L/min, 
increased or decreased in increments of 1L/min. 
HFNC were introduced in late 2013 (used on one patient only in 2012), with consistent use from 2014. No other 
respiratory support guidelines changed during this period. Use of post-natal steroids for ventilator weaning and in 
surfactant delivery by insure (intubate-surfactant-extubate to CPAP) method9,10 increased, in line with international 
trends. 
 
Screening criteria and thresholds for treatment of ROP were based upon UK Retinopathy of Prematurity Guideline11. 
Screening is carried out in house, with treatment provided elsewhere. The ophthalmologist providing screening 
changed in mid-2014, however neither the indications for treatment, nor the single Ophthalmology surgeon providing 
treatment changed during the study period. 
 
Use of ibuprofen is included in the regression analysis. During the study period ibuprofen was first-line 
pharmacotherapy for patent ductus arteriosus (PDA). PDA are confirmed and assessed for haemodynamic significance 
by echocardiography prior to treatment. Early-onset neonatal sepsis is defined as isolation of a bacterial pathogen 
recovered from blood and/or cerebrospinal fluid culture in the first three days of life. 
 
Data were analysed in SPSS statistics12. Normally distributed data were analysed using an unpaired two-tailed t-test. 
Non-normally distributed data were analysed using Mann-Whitney U-test. Chi-squared Pearson co-efficient was used 
for categorical data. Following univariate analysis, multivariate binary logistic regression was performed. Linear data 
were transformed into categorical data for regression analysis. Factors selected for inclusion in the regression analysis: 
smaller gestation (less than 28 weeks in the first analysis and less than 26 weeks in the subgroup analysis), birthweight 
<750g, presence of early onset sepsis, a 5 minute Apgar ≤5, having being ventilated and having received ibuprofen 
were chosen based on evidence suggesting a significant link with BPD13–15, and on baseline differences in our data.  







Patients and follow-up 
There were 573 eligible patients born during the period. Data regarding mortality were missing for two patients. When 
patients were discharged home or transferred to another facility for nursery care without oxygen before 36 weeks 
CGA, they were defined as not having BPD. When discharged to another facility before 36 weeks CGA and still receiving 
oxygen, their data was excluded from BPD calculations. Data regarding ROP stage are included for all patients who 
had at least one ROP screen performed before discharge. Any other missing data were excluded from calculations. 
 
Pre- and post-HFNC group analysis 
There were 256 patients in the pre-HFNC (2010-2012) group and 238 patients in the post-HFNC (2014-2016) group. 
All had GA<30 weeks or birthweight<1500g. Baseline characteristics differed significantly with respect to higher use 
of post-natal steroids (9.7% vs 1.2%, p<0.001) and surfactant (59.7% vs 46.9% p=0.004) in the post-HFNC period. More 
in the post-HFNC were male (55% vs 46.1%, p=0.048), received CPAP treatment (87.8% vs 80.9%, p=0.034) and there 
was a lower proportion of babies with a 5 minute Apgar>5 (84.9% vs 88.7%, p=0.01). There were no other significant 
differences between the two groups in baseline statistics (see Table 1). 
 
Table 1: Baseline characteristics of comparison of groups pre (2010-2012) and post (2014-2016) 
introduction of high-flow nasal cannula. 
 2010-2012 (n=256) 2014-2016 (n=238) Sig  
Birthweight ○  1104g (±273g) 1083g (±320) 0.437✦ 
Gestation ○ 29+1 weeks (±2+5) 28+6 weeks (±2+6) 0.18  ✦ 
Male 118/256 (46.1%) 131/238 (55%) 0.048 ✝ 
Multiple birth 103/256 (40.1%) 91/238 (38.2%) 0.649 ✝ 
Antenatal Steroids 227/256 (88.7%) 215/236 (91.1%) 0.373 ✝ 
5 minute Apgar >5 236/256 (92.2%) 202/238 (84.9%) 0.010 ✝ 
Early onset sepsis 4/256 (1.6%) 7/238 (2.9%) 0.299 ✝ 
Received CPAP 207/256 (80.9%) 209/238 (87.8%) 0.034 ✝ 
Ventilated 127/256 (49.6%) 131/238 (55%) 0.227 ✝ 
Surfactant 120/256 (46.9%) 142/238 (59.7%) 0.004 ✝ 
Post-natal steroids 3/256 (1.2%) 23/238 (9.7%) <0.001 ✝ 
○=mean±SD;  ✦=t-test; ✝=chi-squared   
 
The rate of BPD was significantly higher in the post-HFNC group (35.3% vs 13.1%, p<0.001 (see Table 2).  
 
The rate of death and pneumothorax were similar. Length of stay was slightly longer in the post-HFNC group (median 
59 versus 54 days).  There were significantly more patients with ROP in the post-HFNC group (19% vs 6.1%, p<0.001) 
and more patients with stage two/three ROP compared with stage one. Eleven patients in the post-HFNC group had 
surgery performed for ROP compared with none in the pre-HFNC group. 
 
Following multivariate logistic regression analysis, the effect of being in the post-HFNC group remained a significant 
risk factor BPD development (OR 4.353, 95% CI 2.546 to 7.443, p<0.001), as did having been ventilated (OR 4.01, 95% 
CI 2.035-7.9, p<0.001) and being born at less than 28 weeks (OR 2.616, 95% CI 1.403-4.879). Having a birthweight 
<750g (OR 1.863, 95% CI 0.958-3.622, p=0.067), a 5 minute Apgar ≤5 (OR 1.801, 95% CI 0.883-3.670, p=0.105), having 
received ibuprofen (OR 2.05, 95% CI 0.871-4.823, p=0.1) and having early-onset sepsis (OR 3.127, 95% CI 0.683-14.312, 
p=0.142) did not significantly increase the chance of BPD. Adjusted odds ratios could not be calculated for ROP surgery 




Table 2: Outcomes of patients analysed by cohorts pre (2010-2012) and post (2014-2016) 
introduction of high-flow nasal cannula. 
 2010-2012 (n=256) 2014-2016 (n=238) Sig  
Death 17/256 (6.6%) 13/236 (5.5%) 0.600 ✝ 
BPD 33/251 (13.1%) 82/232 (35.3%) <0.001 ✝ 
Ibuprofen 18/256 (7%) 20/238 (8.4%) 0.567 ✝ 
Pneumothorax 11/256 (4.3%) 14/238 (5.9%) 0.428 ✝ 
Length of stay ✹ 54 days (±38) 59 days (±49.5) 0.01 ▾ 
Any ROP 13/204 (6.1%) 39/205 (19%) <0.001 ✝ 
Maximum stage of ROP 
      -ROP stage 1 6/214 (2.8%) 17/205 (8.3%)  
      -ROP stage 2 5/214 (2.3%) 13/205 (6.3%)   
      -ROP stage 3 2/214 (0.9%) 9/205 (4.4%) <0.001 ✝ 
Surgery for ROP 0/214 (0%) 11/205 (5.4%) 0.001 ✝ 
ROP duration of follow up ○ 37+1 weeks (±4+1) 37+5 weeks (±4+1) 0.27 ✦ 
✹= median (interquartile range); ○=mean±SD;  ✦=t-test; ✝=chi-squared; ▾=Mann 
Whitney U-test 
 
HFNC-eligible group analysis 
From 2010 to 2016, there were 298 infants who were either had CGA<28 weeks, birthweight <750g., were ventilated 
or received surfactant and who did not die before discharge. 160 patients in this ‘HFNC-eligible’ group did not receive 
HFNC, and 138 in the group did receive HFNC. Regarding baseline characteristics those who received HFNC were 
significantly lighter (923g (±270) vs 1044g (±275) vs, p<0.001), had lesser GA (27+1 weeks (±2+0) vs 28+1 weeks (±2+2) 
p<0.001), and differed significantly in other characteristics as detailed in Table 3. 
 
Table 3: Baseline characteristics of patients in ‘HFNC-eligible’ group; those who did not 
receive HFNC compared with those who received HFNC. 
 no HFNC (n=160) HFNC (n=138) Sig 
Birthweight ○  1044g (±275) 923g (±270) <0.001✦ 
Gestation ○ 28+1 weeks (±2+2) 27+1 weeks (±2+0) <0.001 ✦ 
Male 85/160 (53.1%) 73/138 (52.9%) 0.969 ✝ 
Multiple birth 52/160 (32.5%) 45/138 (32.6%) 0.984 ✝ 
Antenatal Steroids 140/160 (87.5%) 130/136 (95.6%) 0.014✝ 
5 minute Apgar >5 145/160 (90.6%) 113/138 (81.9%) 0.027 ✝ 
Early onset sepsis 4/160 (2.5%) 5/138 (3.6%) 0.572 ✝ 
Received CPAP 154/160 (96.3%) 136/138 (98.6%) 0.220 ✝ 
Ventilated 142/160 (88.8%) 125/138 (90.6%) 0.606 ✝ 
Surfactant 141/160 (88.1%) 133/138 (96.4%) 0.009 ✝ 
Post-natal steroids 2/160 (1.3%) 22/138 (15.9%) <0.001 ✝ 
○=mean±SD,  ✦=t-test, ✝=chi-squared   
 
The rate of BPD was higher in those who received HFNC compared to those ‘eligible’ for HFNC who did not receive it 
(68.2% vs 21.6%, p<0.001, Table 4). Having received HFNC remained a significant risk factor for development of BPD 
following logistic regression analysis with an OR of 7.8 (95% CI 4.223-14.423, p<0.001). In this ‘HFNC eligible’ group, 
other significant predictors of BPD were having a birthweight <750g (OR 4.103, 95% CI 1.705-9.874, p=0.002), having 
a 5 minute Apgar≤5 (OR 4.252, 95% CI 1.705-9.874, p=0.003), and having received ibuprofen (OR 3.89, OR 1.460-
10.364, p=0.007). The variables not associated with increased odds of BPD were gestation <26 weeks (OR 2.382, 95% 
CI 0.973-5.831, p-0.057), having been intubated (OR 1.291, 95% CI 0.495-3.363, p=0.601) and early onset sepsis (4.828, 
95% CI 0.679-34.334, p=0.116). 
 
Table 4: Results from patients in ‘HFNC-eligible’ group; those who did not receive HFNC 
compared with those who received HFNC. 
 no HFNC(n=160) HFNC (n=138) Sig 
BPD 33/153 (21.6%) 90/132 (68.2%) <0.001✝ 
Ibuprofen 16/160 (10.0%) 23/138 (16.7%) 0.089✝ 
Pneumothorax 11/160 (6.9%) 12/138 (8.7%) 0.557 ✝ 
Length of stay ✹ 72 (±34) 92.5 (±61) 0.00 ▾ 
Any ROP 14/153 (9.2%) 37/134 (27.6%) <0.0001✝ 
Maximum stage of ROP 
    -ROP stage 1 8/153 (5.2%) 14/134 (10.4%)  
    -ROP stage 2 4/153 (2.6%) 12/134 (9%)  
    -ROP stage 3 2/153 (1.3%) 11/134 (8.2%) <0.001 ✝ 
Surgery for ROP 0/153 (0%) 13/134 (9.7%) <0.001 ✝ 
ROP duration of follow up ○ 38+1 weeks (±3+6) 39+4 weeks (±4+0) 0.002✦ 





Our study highlights that the introduction of HFNC can lead to an increase in rates of BPD among premature infants 
(birthweight<1500g or <30 weeks GA). This was not offset by any decrease in mortality rate. Length of stay (LOS) was 
also longer in the post-HFNC group. Following the introduction of HFNC, there were more infants with a 5 minute 
Apgar≤5 and more infants receiving CPAP, perhaps indicating higher baseline co-morbidity. However, on multivariate 
analysis a VLBW infant belonging to the post-HFNC group had a 4.5 fold increased risk of developing BPD, indicating 
that exposure to HFNC alone is a significant risk factor for development of BPD, even in the context of an increased 
baseline risk. However, it must also be acknowledged, that clinicians’ perceptions of HFNC as ‘gentler’ may be 
contributing to slower weaning of this mode of respiratory support (compared to nCPAP), and slower subsequent 
transition onto low-flow 02 and room air, which would cause more BPD by our definition (i.e. oxygen dependence at 
36 weeks CGA) and a longer LOS. 
 
Our second analysis focused on those babies who were ‘eligible’ for HFNC (i.e. any of GA<28weeks, birthweight <750g, 
ventilated or received surfactant and survived to discharge) but did not receive it compared to those infants who did 
receive HFNC support across 2010-2016 inclusive. In this analysis, again receiving HFNC was associated with 
significantly more BPD. Again, in this analysis of ‘HFNC-eligible’ infants, LOS was longer in those who received HFNC 
compared to those who did not. Although baseline characteristics (smaller gestation and birthweight, higher 
proportion with low 5-minute Apgar, higher rates of surfactant use indicating underlying respiratory distress) showed 
the group receiving HFNC to be likely to develop BPD at baseline, the risk associated with receiving HFNC was again 
persistent after multivariate analysis, with these infants having a 7.8 fold increased risk of developing BPD. Similarly, 
to the analysis above, clinicians’ attitude to HFNC must be kept in mind when interpreting these results. 
 
This study also looked at the effect of HFNC on the development of ROP. Following introduction of HFNC, the rate of 
any ROP increased, along with the rate of more severe ROP and number of infants treated surgically. The same 
differences were observed when those receiving HFNC within the ‘HFNC-eligible’ group were compared to those who 
did not receive HFNC in this group. Again, while this increase in ROP can be partly attributed to a population that were 
generally more unwell and in receipt of more intervention (as in pre and post-HFNC analysis) or generally smaller and 
lesser GA (in the ‘HFNC-eligible’ analysis), in the context of increased BPD and likely associated increased oxygen 
exposure in groups receiving more HFNC, the role of HFNC in contributing to this pathology must be considered. 
 
Limitations of our study include differences in baseline characteristics, and that we have not recorded the number of 
days spent on HFNC for each infant, so there may be inconsistencies in the degree of exposure. Regarding 
ophthalmological outcomes, this study is limited in that the individuals screening our premature infants for ROP 
changed during the duration of the study, however neither the indications for surgical treatment nor the single 
surgeon providing the surgical treatment changed throughout the entire study period for all the infants treated for 
ROP. 
 
In this study, HFNC was used as a tool for weaning from CPAP. Only one available RCT evaluated a population similar 
to ours (birthweight≤1500g, GA<32 weeks) and employed similar weaning protocols2. This group showed no difference 
in respiratory or ophthalmological outcomes. The other two published trials3,4 studied older infants (mean GA 31 
weeks) and did not use low-flow nasal cannula Oxygen in weaning, making comparisons with this study difficult. HFNC 
studies also use differing flow-rates, a fact mirrored in a recent survey of centres in the UK16, and a factor that makes 
comparing studies difficult. Retrospective studies have also been complicated by the fact that use of HFNC often 
selects out smaller, sicker infants (who have had more post-natal steroids and more ventilator courses)5-7. This effect 
was seen in our second analysis. Prospective and retrospective studies have been inconsistent in their outcomes 
regarding ROP2,5-8. In our study, use of HFNC was associated with longer LOS in both analyses. LOS was not commented 
on in the Soonsowad trial2 and the two other RCTs had conflicting results3,4. Again it must be noted that the latter two 
trials examined a population dissimilar to ours. 
 
HFNC has been shown to be ineffective as primary respiratory support for premature babies2.Previous questions of a 
benefit in achieving oral feeds over CPAP have been contradicted by a recent RCT18. While the above studies 
demonstrate the lack of benefit of HFNC, we believe this study raises significant questions about its safety. In summary, 
this study raises the concern that use of HFNC to wean infants from CPAP may have adverse effects on respiratory and 
ophthalmological outcomes in premature VLBW infants. While there are many perceived benefits to HFNC, with its 
use becoming widespread across many neonatal units worldwide, we believe the use of HFNC as a weaning tool from 
CPAP needs to be further evaluated with an adequately powered RCT before it becomes the accepted norm. 
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